These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 39248222)

  • 1. Glyburide use is associated with a greater likelihood of mortality or rehospitalization after acute coronary syndrome compared to gliclazide use in adults with type 2 diabetes: A cohort study.
    Long W; Light PE; Simpson SH
    Diabetes Obes Metab; 2024 Nov; 26(11):5408-5419. PubMed ID: 39248222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.
    Abdelmoneim AS; Eurich DT; Gamble JM; Johnson JA; Seubert JM; Qiu W; Simpson SH
    Diabetes Obes Metab; 2014 Jan; 16(1):22-9. PubMed ID: 23802997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
    Huang Y; Abdelmoneim AS; Light P; Qiu W; Simpson SH
    J Diabetes Complications; 2015 Mar; 29(2):196-202. PubMed ID: 25534984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes.
    Abdelmoneim AS; Eurich DT; Senthilselvan A; Qiu W; Simpson SH
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1186-1195. PubMed ID: 27102581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population.
    Juurlink DN; Gomes T; Shah BR; Mamdani MM
    Diabet Med; 2012 Dec; 29(12):1524-8. PubMed ID: 22913620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
    Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
    Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide.
    Clemens KK; McArthur E; Dixon SN; Fleet JL; Hramiak I; Garg AX
    Can J Diabetes; 2015 Aug; 39(4):308-16. PubMed ID: 25840942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
    Khalangot M; Tronko M; Kravchenko V; Kovtun V
    Diabetes Res Clin Pract; 2009 Dec; 86(3):247-53. PubMed ID: 19796836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
    Huang HK; Yeh JI
    Diabetes Res Clin Pract; 2019 Jun; 152():103-110. PubMed ID: 31108137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.
    Monami M; Balzi D; Lamanna C; Barchielli A; Masotti G; Buiatti E; Marchionni N; Mannucci E
    Diabetes Metab Res Rev; 2007 Sep; 23(6):479-84. PubMed ID: 17385195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes?
    Nagendran J; Oudit GY; Bakal JA; Light PE; Dyck JR; McAlister FA
    Diabetes Obes Metab; 2013 Nov; 15(11):1022-8. PubMed ID: 23668425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy.
    Saberi M; Ramazani Z; Rashidi H; Saberi A
    Vasc Health Risk Manag; 2020; 16():241-248. PubMed ID: 32606720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice.
    Lee YH; Lee CJ; Lee HS; Choe EY; Lee BW; Ahn CW; Cha BS; Lee HC; Balkau B; Kang ES
    Diabetes Metab; 2015 Jun; 41(3):208-15. PubMed ID: 25687901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes.
    Katakami N; Yamasaki Y; Hayaishi-Okano R; Ohtoshi K; Kaneto H; Matsuhisa M; Kosugi K; Hori M
    Diabetologia; 2004 Nov; 47(11):1906-13. PubMed ID: 15565373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation approach can significantly influence oral glucose-lowering drugs total mortality risks in retrospective cohorts of type 2 diabetes mellitus patients.
    Khalangot M; Kovtun V
    Curr Diabetes Rev; 2014; 10(5):336-42. PubMed ID: 25336066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glibenclamide vs gliclazide in type 2 diabetes of the elderly.
    Tessier D; Dawson K; Tétrault JP; Bravo G; Meneilly GS
    Diabet Med; 1994 Dec; 11(10):974-80. PubMed ID: 7895463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.
    van der Wal PS; Heine RJ
    Diabetes Res Clin Pract; 2001 May; 52(2):103-11. PubMed ID: 11311964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents.
    Chan SP; Colagiuri S
    Diabetes Res Clin Pract; 2015 Oct; 110(1):75-81. PubMed ID: 26361859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulphonylureas and cancer: a case-control study.
    Monami M; Lamanna C; Balzi D; Marchionni N; Mannucci E
    Acta Diabetol; 2009 Dec; 46(4):279-84. PubMed ID: 19082520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes.
    Räkel A; Renier G; Roussin A; Buithieu J; Mamputu JC; Serri O
    Diabetes Obes Metab; 2007 Jan; 9(1):127-9. PubMed ID: 17199728
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.